Tarsus Pharmaceuticals Acquires Alkeus for $800M to Enter Stargardt Disease Race
In a major consolidation of the ophthalmic pipeline space, Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals in a transaction valued up to $800 million. Under the terms of the agreement, Tarsus will pay $450 million upfront—consisting of $270 million in cash and $180 million in Tarsus common stock—with an additional $350 million in potential regulatory and commercial milestones.
Gildeuretinol: The Centerpiece of the Deal
The crown jewel of the acquisition is gildeuretinol (formerly ALK-001), a once-daily oral therapy designed to treat Stargardt disease, a rare, progressive inherited retinal disorder that causes central vision loss. Gildeuretinol is engineered to reduce the formation of toxic vitamin A dimers (lipofuscin) on the retina while preserving the visual cycle.
The asset is currently being evaluated in the late-stage Phase 3 NORTHSTAR trial (NCT07419334), which dosed its first patient in June 2026. Topline data from NORTHSTAR are anticipated in the second half of 2029.
A Highly Competitive Stargardt Landscape
Stargardt disease currently has no FDA-approved treatments, making the race to market highly competitive. With the acquisition of Alkeus, Tarsus positions itself as a major contender, though it faces formidable rivals:
- Belite Bio: Currently the frontrunner, Belite Bio completed its rolling New Drug Application (NDA) submission to the FDA for its oral retinol-binding protein 4 (RBP4) antagonist, tinlarebant, on June 12, 2026. The submission is supported by positive data from its pivotal Phase 3 DRAGON trial (see FDA Accepts Belite Bio's Tinlarebant NDA for Priority Review in Stargardt Disease).
- Ocugen: Advancing its gene therapy OCU410ST, which is on track to report topline Phase 1/2 clinical data in the second quarter of 2027.
- Nanoscope Therapeutics: Moving its optogenetic gene therapy MCO-010 into Phase 3 clinical development after posting positive Phase 2 STARLIGHT efficacy results.
For Tarsus, the takeover bolsters its growing eye care franchise, building on its previous $565 million acquisition of iRenix Medical and its ocular antiseptic candidate, IRX-101.
"Tarsus Pharmaceuticals has forged a takeover deal with Alkeus Pharmaceuticals worth up to $800m, adding a Stargardt disease asset with possible 'blockbuster potential' to its pipeline and bolstering its standing in the ophthalmology space," reported Pharmaceutical Technology.